ScoreWhy is Novelix Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.76%
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.83
2
With a growth in Net Profit of 88.68%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(Q) At Rs 48.40 cr has Grown at 128.1% (vs previous 4Q average)
- PBDIT(Q) Highest at Rs 1.31 cr.
- OPERATING PROFIT TO NET SALES(Q) Highest at 2.71%
3
With ROE of 7.1, it has a Expensive valuation with a 4.3 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 116.96%, its profits have risen by 192%
4
Consistent Returns over the last 3 years
- Along with generating 116.96% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Novelix Pharma. should be less than 10%
- Overall Portfolio exposure to Retailing should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Novelix Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Novelix Pharma.
116.96%
2.11
55.34%
Sensex
8.53%
0.73
11.73%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
153.19%
EBIT Growth (5y)
29.98%
EBIT to Interest (avg)
-1.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
1.13
Tax Ratio
22.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-5.98%
ROE (avg)
0.76%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
60
Industry P/E
32
Price to Book Value
4.28
EV to EBIT
46.04
EV to EBITDA
44.71
EV to Capital Employed
4.48
EV to Sales
0.85
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.97%
ROE (Latest)
7.11%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
NET SALES(Q)
At Rs 48.40 cr has Grown at 128.1% (vs previous 4Q average
PBDIT(Q)
Highest at Rs 1.31 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 2.71%
PBT LESS OI(Q)
Highest at Rs 1.28 cr.
PAT(Q)
Highest at Rs 1.00 cr.
EPS(Q)
Highest at Rs 0.58
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Novelix Pharma.
Net Sales - Quarterly
At Rs 48.40 cr has Grown at 128.1% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 21.22 CrMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Net Sales - Quarterly
Highest at Rs 48.40 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.31 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 2.71%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.28 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1.00 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.58
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
